"Patience is a Super Power" - "The Money is in the waiting"
Showing posts with label Tesla. Show all posts
Showing posts with label Tesla. Show all posts

Sunday, January 18, 2026

A retail investors focused report on Robotics and Humanoids for January 2026

                                                

Humanoids and robotics (2026+) — market potential, reality checks, and the best-positioned public companies for retail investors!

Executive summary

Humanoid robotics is moving from “AI demos” to early industrial pilots, but the investable opportunity set for public-market retail investors still skews toward enablers and bottleneck suppliers (actuation, precision gearing, sensors/analog, and critical materials) rather than pure-play humanoid OEMs (many are private). The market’s ceiling could be very large, but credible forecasts vary widely—reflecting real uncertainty around unit economics, reliability, safety, and throughput.

Recent institutional research/media coverage frames the humanoid opportunity as potentially large (e.g., Barclays’ optimistic scenario suggests ~$200B by 2035), while other reputable forecasts are far more conservative (e.g., Goldman Sachs projecting ~$38B by 2035).


1) Market size: a wide range is the honest answer

Forecasts differ substantially because commercialization hinges on three variables that are still unproven at scale:

  1. Robot cost trajectory (BOM + manufacturing yield + warranty)

  2. Task productivity (cycle times, failure modes, autonomy level)

  3. Operating model (deployment, monitoring, maintenance, safety compliance)

Examples of the spread:

  • Goldman Sachs (Feb 2024): humanoid TAM projected at ~$38B by 2035.

  • Barclays (reported Jan 2026): an optimistic scenario as high as ~$200B by 2035.

  • ABI Research (2025 chart/data): humanoids “essentially non-existent” today, but forecasts ~$6.5B by 2030 (with very high growth assumptions).

  • Grand View Research: $1.55B (2024) → ~$4.04B (2030) (more modest CAGR).

Investor implication: 

This is a classic “big upside, high model risk” market

It rewards owning the picks-and-shovels that get pulled forward even if humanoid adoption is slower than hype.


2) What is actually happening now (signal vs. noise)

The most credible near-term demand is industrial and logistics pilots where:

  • tasks are repetitive,

  • environments are semi-structured,

  • ROI can be measured,

  • supervision is acceptable early.

Evidence of real pilot activity:

  • BMW + Figure: BMW publicly described testing humanoids in production for ergonomically difficult tasks (2024).

  • Figure updates highlight operational learnings from BMW deployments (company statements).

  • Mercedes-Benz + Apptronik: Reuters reported Mercedes taking a stake and testing humanoid robots in factories (2025).

  • Amazon + Agility Robotics (Digit): Amazon described Digit as part of its robotics initiatives; Agility stated deliveries to partner-program customers in 2024 and broader availability in 2025.

Reality check: “Mass production in 2026” headlines exist (e.g., some OEM statements), but the market should assume limited volumes first, with scaling gated by reliability and cost.


3) Where the money is likely to accrue first

For public-market investors, the best risk-adjusted exposure is usually in components with:

  • high switching costs (qualification + reliability),

  • structural scarcity (capacity-constrained suppliers),

  • cross-OEM demand (everyone needs the same parts).

The four bottlenecks that matter most

  1. Actuators & motion (motors + drives + mechanical integration)

  2. Precision gearing/reducers (strain-wave / RV)

  3. Sensors + analog/power (the “nervous system”)

  4. Rare-earth magnets/materials (NdPr → high-performance motors)


4) “Best positioned to grow and prosper”: top public-company shortlist (retail-investor accessible)

Below are five names I would prioritize for a Canadian or U.S. retail investor seeking the “supplier-first” humanoid/robotics thesis, with an emphasis on “under-the-radar” relative to megacap OEMs.

1) Schaeffler (Germany; often accessible via international brokerage / ADR depending on platform)

Why it fits: Schaeffler is explicitly positioning as a humanoid component supplier, focusing on key components like actuators and announcing multiple humanoid-related initiatives and partnerships.
Why it’s attractive for your scenario: Direct “picks-and-shovels” posture for humanoids, but backed by a broader industrial/mechatronics base.

2) Nabtesco (Japan; often accessible via international brokerage)

Why it fits: Precision reducers are a gating item in high-DOF robots. Nabtesco states it has ~60% share (company estimate) in precision reduction gears for medium-to-large industrial robot joints.
Why it matters: If humanoids scale, demand for compact, high-torque, low-backlash joints scales with it—often faster than OEM unit growth.

3) Harmonic Drive Systems (Japan; sometimes available OTC depending on broker)

Why it fits: Strain-wave gearing is foundational for compact humanoid joints. Harmonic Drive has invested to expand capacity historically (illustrative of demand pressure).
Why it matters: In many humanoid designs, the reducer is a cost and availability bottleneck.

4) MP Materials (NYSE: MP)

Why it fits: Rare-earth magnets are strategic and supply-constrained. MP has a major DoD-backed buildout plan including a second U.S. magnet facility (“10X Facility”) expected to begin commissioning in 2028, plus other downstream steps to expand domestic supply.
Why it matters: Humanoids are “motor-heavy.” If unit volumes rise, the magnet/motor supply chain becomes an enabling constraint, not an afterthought.

5) Texas Instruments (NASDAQ: TXN)

Why it fits: Robots are, at scale, an analog/power and motor-control story as much as an AI story. TI is a long-cycle supplier of analog, power management, and embedded control components that appear across industrial automation and robotics. (This is the “quiet compounder” category.)
Why it matters: Even if humanoids take longer, robotics in general (industrial automation) continues to consume these components.


5) A practical “Humanoid + Robotics” watchlist map (so you can expand beyond the top five)

If you want a deeper bench to follow, here’s how I would structure it:

A) Mechanical bottlenecks (high leverage to humanoid scaling)

  • Nabtesco (precision reducers)

  • Harmonic Drive Systems (strain-wave gears)

  • Schaeffler (actuators / humanoid components)

B) Materials constraint / geopolitics

  • MP Materials (NdPr / magnets supply chain buildout)

C) Robotics “nervous system”

  • Texas Instruments (analog/power/control)

  • Analog Devices / onsemi / STMicro (similar thesis: sensing + power + industrial IO)

D) OEM activity (watch for proof of volume, but don’t rely on it)

  • Tesla Optimus timelines and commentary can move sentiment, but execution is uncertain.

  • Automotive factories remain a credible first beachhead (BMW/Figure; Mercedes/Apptronik).


6) Key risks retail investors should underwrite

  1. Adoption takes longer than headlines imply (safety, uptime, maintenance)

  2. Unit economics disappoint (BOM cost vs. task productivity)

  3. Component commoditization (if supply expands quickly and pricing power fades)

  4. Policy/geopolitics (rare earths, export controls, onshoring)

  5. Valuation risk (many robotics-adjacent names can get “theme-priced”)


7) What I would monitor quarterly (simple retail checklist)

  • Pilot-to-rollout conversions: Are pilots turning into multi-site deployments? (BMW/Figure-type updates)

  • Component capacity expansions: reducer/gear output, actuator supply agreements, magnet capacity milestones

  • Cost-down evidence: BOM reductions and service/warranty experience

  • Regulatory & safety posture: workplace deployment standards, incident rates

  • OEM “real work” metrics: hours run, tasks completed, supervised autonomy trends (when disclosed)


Bottom line

For a Canadian/U.S. retail investor who wants “humanoids + robotics” exposure without betting on which humanoid brand wins, the strongest setup is a basket centered on:

  • Schaeffler + Nabtesco + Harmonic Drive (mechanical bottlenecks),

  • MP Materials (materials constraint),

  • Texas Instruments (control/power backbone).Humanoids + robotics: U.S./TSX-only “under-the-radar” supplier exposure (retail investor report)

Why suppliers can be the cleaner bet than humanoid OEMs

Humanoids may become a major end-market, but near-term commercialization is still likely to be pilot-heavy and volume-light versus the hype cycle. In that environment, the best public-market risk/reward often sits with picks-and-shovels suppliers that benefit from robotics broadly (industrial automation, mobile robots, warehouse systems) while retaining upside if humanoids scale.

The most “unavoidable” supplier bottlenecks across most humanoid designs are:

  • Actuation + motion control (motors, drives, servo loops)

  • Sensing (vision, depth, inertial, force/torque, safety sensing)

  • Power conversion (battery management, motor drivers, DC/DC)

  • Materials (especially rare-earth magnets for high-torque motors)

Below are five U.S./TSX-listed names I would prioritize to follow and/or consider for this “supplier-first humanoids” thesis, emphasizing companies that are not the obvious mega-cap humanoid headlines.


5 companies (U.S./TSX-only)

1) MP Materials (NYSE: MP) — rare-earth magnets: a motors-and-actuators constraint

What it supplies: NdPr materials and a U.S.-centric rare-earth/magnet supply chain buildout.
Why it fits humanoids: Humanoids are “motor-dense.” If unit volumes scale, magnet availability and geopolitics can become a gating factor.
What makes it investable now: MP has a major U.S. Department of Defense public-private partnership that includes (as reported) a 10-year price floor for NdPr and a 10-year offtake commitment tied to its planned “10X Facility,” with operations expected by 2028.
Key risks: commodity/price volatility, execution on downstream magnet capacity, political/regulatory risk.


2) Onsemi (NASDAQ: ON) — “robotics nervous system”: sensing + power + motor control

What it supplies: Industrial automation/robotics-facing portfolios in intelligent power, image sensing, and motor control—critical building blocks in robots of all types. onsemi explicitly positions offerings for robotics/industrial automation and “smart and mobile robotics” use cases.
Why it fits humanoids: Regardless of the robot brand, you need robust power electronics, sensing, and motor drive/control to run many joints safely and efficiently.
Key risks: cyclical semiconductor demand, competitive pressure, customer concentration in some end-markets.


3) Moog (NYSE: MOG.A / MOG.B) — motion control components that translate to advanced robotics

What it supplies: Precision motion components (e.g., motors and motion subsystems) that Moog markets directly for robotics, including performance-oriented motor solutions and broader “robotics and autonomous solutions” positioning.
Why it fits humanoids: Humanoids are essentially a stack of tightly coordinated motion axes. Suppliers with deep “hard-motion” engineering and reliability culture can see pull-through demand as robotics moves from demo to uptime-driven deployments.
Why it’s “under-followed”: It is not typically the first name retail investors associate with humanoids, despite direct robotics positioning.
Key risks: industrial cycle sensitivity; Moog is diversified—robotics may be a smaller slice.


4) Celestica (TSX: CLS / NYSE: CLS) — scaling hardware: manufacturing, robotics-capital equipment, and “physical AI” infrastructure

What it supplies: End-to-end design/manufacturing and supply-chain solutions with meaningful exposure to industrial/capital equipment and other complex hardware verticals; Celestica’s own materials highlight “Robotics and Automated Capital Equipment Solutions.”
Why it fits humanoids: If humanoids start scaling, the winners are not only the designers; they are also the companies that can manufacture complex electromechanical systems reliably and at cost. Celestica is a credible “scaling enabler” rather than a single-OEM bet.
Key risks: margin discipline in manufacturing services, customer concentration, the robotics linkage is more “enabling” than direct component IP.


5) Texas Instruments (NASDAQ: TXN) — the quiet backbone: analog + embedded for industrial automation and robotics

What it supplies: Analog and embedded components used across industrial automation; TI explicitly frames building “smarter, safer robotics” within its industrial automation resources.
Why it fits humanoids: The scaling of robots is not only an AI story; it is a power + sensing + control-loop story. TI benefits from broad robotics/automation growth even if humanoids take longer than expected.
Key risks: cyclical industrial demand; lower “humanoid purity” (but higher resilience).


How I would use these as a retail investor (practical approach)

A) Build a “supplier basket” instead of a single bet

  • Materials constraint: MP

  • Power/sensing platform: onsemi + TI

  • High-performance motion: Moog

  • Scaling/manufacturing enabler: Celestica

This creates exposure to multiple points of the humanoid BOM and scaling chain, while still benefiting from robotics/automation generally.

B) What to monitor (quarterly checklist)

  1. Evidence of scaling: multi-site deployments, not just pilots (OEM-agnostic signal)

  2. Component tightness: commentary around motor supply, magnets, power electronics lead times

  3. Cost-down progress: any credible “cost per robot” declines or simplified actuator designs

  4. Safety + uptime: incidents, warranty, and maintainability disclosures (rare but important)

  5. Capex milestones: especially MP’s magnet buildout timeline and downstream execution


Clear-eyed risks (what can go wrong)

  • Humanoids under-deliver on ROI versus simpler automation (cobots, AMRs) and adoption is slower

  • Component commoditization if supply ramps quickly (reducing pricing power)

  • Theme valuations compress even if fundamentals improve

  • Geopolitical shock (rare earths, export controls) can be both a tailwind and a volatility driver


Bottom line (U.S./TSX-only)

If your objective is “humanoids upside, but with supplier resilience,” my top U.S./TSX-only set to follow/investigate first is:

MP (materials bottleneck) + onsemi (sensing/power) + TI (control backbone) + Moog (motion) + Celestica (scale/manufacturing enabler).

-----------------------------------------------------------------------------------------------------

Below is a U.S./TSX-only model portfolio framework designed for retail investors who want exposure to humanoids and robotics via suppliers, not just robot OEMs.

The portfolios use the same five names, but weight them differently depending on whether the goal is capital preservation with theme participation (Conservative) or maximum thematic torque (Aggressive).

Universe (unchanged across both models):

  • MP – MP Materials (rare-earth magnets; motors & actuators bottleneck)

  • ON – onsemi (power electronics, sensors, motor control)

  • TXN – Texas Instruments (analog & embedded “robot nervous system”)

  • MOG.A / MOG.B – Moog (precision motion & robotics components)

  • CLS (TSX/NYSE) – Celestica (hardware scaling & robotics-capital equipment enabler)


$25,000 Portfolio

Conservative Model

Focus: resilience, cash flow, and exposure to robotics even if humanoids take longer

RankCompanyWeightAllocation
1Texas Instruments (TXN)30%$7,500
2onsemi (ON)25%$6,250
3Celestica (CLS)20%$5,000
4Moog (MOG.A/B)15%$3,750
5MP Materials (MP)10%$2,500
Total100%$25,000

Profile:

  • TXN and ON anchor the portfolio with durable industrial cash flows.

  • CLS gives “physical AI” scaling exposure without single-OEM risk.

  • Moog adds motion leverage.

  • MP is the asymmetric tail option if humanoids/motors scale rapidly.

Risk Character:
Low-to-moderate volatility; theme exposure without over-reliance on speculative adoption curves.


Aggressive Model

Focus: torque to humanoid adoption and supply-chain bottlenecks

RankCompanyWeightAllocation
1MP Materials (MP)30%$7,500
2Onsemi (ON)25%$6,250
3Moog (MOG.A/B)20%$5,000
4Celestica (CLS)15%$3,750
5Texas Instruments (TXN)10%$2,500
Total100%$25,000

Profile:

  • MP becomes the core thesis expression (motors = magnets).

  • ON and Moog concentrate exposure to actuation, sensing, and control.

  • TXN becomes ballast rather than anchor.

Risk Character:
Higher volatility; returns more sensitive to humanoid headlines, magnet policy, and robotics CAPEX cycles.


$50,000 Portfolio

Conservative Model

RankCompanyWeightAllocation
1Texas Instruments (TXN)30%$15,000
2onsemi (ON)25%$12,500
3Celestica (CLS)20%$10,000
4Moog (MOG.A/B)15%$7,500
5MP Materials (MP)10%$5,000
Total100%$50,000

Aggressive Model

RankCompanyWeightAllocation
1MP Materials (MP)30%$15,000
2onsemi (ON)25%$12,500
3Moog (MOG.A/B)20%$10,000
4Celestica (CLS)15%$7,500
5Texas Instruments (TXN)10%$5,000
Total100%$50,000

Saturday, August 16, 2025

If North American consolidation in the REE/Li market is in the cards, AVL looks to be a consolidation lottery ticket!

 

 

Avalon Advanced Materials (TSX: AVL)

Consolidation Driver in the North American REE & Lithium Markets

(Some penny stocks shouldn't be overlooked. I believe AVL is one of those)


1. Strategic Position in REEs

  • Nechalacho Project (NWT, Canada):

    • One of the most advanced REE deposits in North America.

    • 2013 DFS gave an after-tax NPV of ~USD $900M (~C$1.2B).

    • Contains both light and heavy REEs critical for defense, communications, and EV motors.

    • Currently split with Vital Metals (North T Zone) → clear consolidation target for a single operator.

  • AVL’s Basal Zone holds the majority of resources, positioning the company as a natural consolidator or takeover target.


2. Strategic Position in Lithium

https://www.vmcdn.ca/f/files/nob/avalon-advanced-materials-thunder-bay-site-sign-2.png%3Bw%3D960https://www.vmcdn.ca/f/files/nob/avalon-thunder-bay-site-placement-map.png%3Bw%3D960
  • Thunder Bay Lithium Hydroxide Facility (Ontario):

    • 2024 PEA showed C$4.1B after-tax NPV and 48% IRR.

    • Only planned midstream processing hub linking Ontario/Northern lithium deposits with Southern Ontario EV/battery manufacturing.

    • A rare “ready-made” piece of infrastructure for OEMs or lithium miners seeking to capture IRA credits.

  • Lithium Deposits: Separation Rapids (Kenora), Snowbank, and Lilypad → resource pipeline for Thunder Bay facility.


3. Why Avalon is a Consolidation Prize

  • Few companies combine REE + lithium assets in one portfolio.

  • AVL offers both upstream resources (REEs, lithium deposits) and midstream processing (Thunder Bay).

  • Consolidating AVL allows a buyer to secure:

    • Long-life REE supply (Nechalacho).

    • A North American lithium hydroxide plant.

    • Eligibility for U.S./Canadian government incentives under the IRA and Canadian Critical Minerals Strategy.


4. Potential Suitors & Rationale

  • Critical Metals (CRML): Synergy with Tanbreez (Greenland); cross-Atlantic REE strategy.

  • Vital Metals (VML): Logical consolidator of Nechalacho (eliminate split ownership).

  • MP Materials (MP): U.S. REE giant; Avalon secures Canadian REE + lithium foothold.

  • Lynas Rare Earths (LYC): Expansion into North America to diversify from Australia.

  • Lithium Americas / Piedmont Lithium: Thunder Bay plant is the missing midstream link.

  • Tesla, GM, Ford: Direct EV/battery makers securing feedstock & processing capacity.


5. Buyout Valuation & Escalation Potential

  • Current Market Cap: ~C$22–25M (@ ~C$0.04/share).

  • Risk-adjusted strategic value: ~C$300–600M (C$0.50–0.85/share).

  • Likely opening bid: ~C$1/share (~C$637M).

  • If multiple suitors compete: Escalation toward C$1.75–2.10/share (~C$1.1–1.3B).

  • Extreme scenario (Tesla/MP with gov’t backing): Possible bid north of C$2/share if Thunder Bay DFS confirms economics + IRA/Defense contracts lock in demand.


6. Investment Thesis

  • Underappreciated value: Market assigns only ~C$25M to assets with multi-billion NPVs.

  • Strategic location: Canada = politically secure jurisdiction, aligned with U.S. supply-chain policies.

  • Consolidation catalyst: Split ownership at Nechalacho and fragmented lithium supply chain make AVL a natural acquisition target.

  • Bidding war potential: With REE + lithium both on the strategic critical list, more than one suitor is almost inevitable.


Conclusion

Avalon (AVL) is grossly undervalued relative to its assets. From a consolidation standpoint, it represents one of the few opportunities for REE and lithium players to secure a vertically integrated North American platform.

  • Entry today (~C$0.04/share) offers exposure to a potential 25×–50× re-rating if a takeover unfolds.

  • A realistic acquisition could settle around C$1–1.25/share, with upside to C$2/share in a competitive bidding war.


👉 In short: AVL is a textbook “strategic consolidation play” in the REE market, with built-in lithium upside. The mismatch between current valuation and strategic value makes it highly attractive for patient investors — and a natural spark for a bidding war.


The three most likely suitors (MP Materials, Lynas, and CRML) would gain by acquiring Avalon Advanced Materials (AVL), and that could push bidding toward the C$2/share mark.


Takeover Case Comparison: Who Benefits Most from Buying Avalon (AVL)?


1. MP Materials (NYSE: MP)

Profile: Largest U.S. REE producer (Mountain Pass, California), backed by U.S. defense and IRA policies.

What They Gain From AVL:

  • Nechalacho REE deposit: Adds a second North American REE source, diversifying away from Mountain Pass.

  • Thunder Bay lithium hydroxide facility: Midstream processing capacity in Canada → critical for EV battery OEM contracts.

  • Canadian footprint: Strengthens IRA eligibility and helps qualify U.S. automakers for mineral sourcing credits.

  • Geopolitical leverage: Control over both U.S. and Canadian REEs makes MP the undisputed North American champion.

Why They Might Pay Up:

  • MP has the balance sheet (US$5B+ market cap) and political support to pay C$1.50–2.00/share for AVL if it locks out Lynas or CRML and secures Canada as a “REE & lithium fortress.”


2. Lynas Rare Earths (ASX: LYC)

Profile: World’s largest REE producer outside China (Mount Weld mine, Australia), with Japanese government support.

What They Gain From AVL:

  • Nechalacho REE deposit: A second production center outside Australia → diversification + North America expansion.

  • Thunder Bay facility: Processing hub ties them into the EV battery value chain — an area where Lynas currently lacks direct presence.

  • Strategic partnerships: Japanese offtakers (Toyota, Sojitz, JOGMEC) could be extended into Canada.

  • Geopolitical insurance: A hedge against China disruptions and over-reliance on Australia/Malaysia operations.

Why They Might Pay Up:

  • Lynas is under pressure to expand capacity in Western-friendly jurisdictions.

  • Could justify C$1.25–1.75/share, possibly more if MP enters the bidding.


3. Critical Metals Corp. (NASDAQ: CRML)

Profile: Developer of the Tanbreez REE project in Greenland, currently advancing a Definitive Feasibility Study (DFS).

What They Gain From AVL:

  • Nechalacho REE deposit: Complements Tanbreez, giving CRML two of the world’s largest non-China REE resources.

  • Thunder Bay facility: Instant midstream processing — CRML’s missing piece for vertical integration.

  • Lithium exposure: Expands portfolio beyond REEs, adding lithium hydroxide production → higher relevance to EV/battery markets.

  • U.S./Canadian critical minerals politics: Strengthens case for DOE/DoD funding, partnerships, and offtake deals.

Why They Might Pay Up:

  • CRML is smaller than MP or Lynas, so financing a C$1–2/share bid would require partnerships or equity raises.

  • But the strategic synergy is enormous — owning both Tanbreez and Nechalacho could make CRML a takeover target itself later.

  • Likely to bid in the C$1.00–1.25/share range, but might stretch higher if MP/Lynas enter the fight.


Who Would Push the Bidding War Toward $2?

  • MP Materials: Most likely, because of financial capacity and U.S. strategic interest.

  • Tesla or GM/Ford (dark horses): If they step in for vertical integration and secure lithium hydroxide, they could shock the market with a C$2+ bid.

  • Lynas: Would bid aggressively if threatened by MP’s Canadian expansion.

  • CRML: May trigger the bidding, but less likely to win against giants without financial partners.


Investment Takeaway

  • AVL’s unique REE + lithium + midstream combo makes it the only Canadian consolidator play with immediate strategic relevance.

  • Base case: Takeover at C$1–1.25/share (C$637M–800M).

  • Bidding war case: Escalation to C$1.75–2.00/share (~C$1.1–1.3B).

  • Extreme upside: If OEMs or governments step in, C$2.50–3.00/share is possible, though less likely until DFS updates are complete.


👉 This is why AVL at ~C$0.04 today looks like a consolidation lottery ticket



the downside is limited, but the upside is multiples higher if a bidding war ignites

Ed Note: Disclosure: We've been acquiring shares in AVL UCU CRML

Related Articles:

REEs are critical to all cutting edge technologies now and early investors should be rewarded! We just took a small position in our 4th REE stock-CRML


Monday, March 24, 2025

USA Presidential elections have a real impact on stock markets. So, How can one position oneself in the first year?


If we use the election cycle as a guide, especially for U.S. presidential elections, there are some historical patterns investors often pay attention to:

  • Post-election years (like 2025) often bring policy shifts (stimulus, deregulation, defense spending, etc.) that affect certain sectors.

  • The first year of a presidency often includes new government programs, spending packages, and regulatory changes—this can mean big moves for companies exposed to government contracts or regulation.

So, if we go by history and themes that often play well in post-election years, here are a few sectors and example companies to watch for potential gains in 2025:


⚙️ 1. Defense & Aerospace

New administrations (regardless of party) often increase defense budgets or reallocate them. Global tensions also drive this.

  • Lockheed Martin (LMT)

  • Northrop Grumman (NOC)

  • Palantir Technologies (PLTR) – also benefits from defense + AI + government contracting.


🏗️ 2. Infrastructure & Clean Energy

If a new or returning president pushes for infrastructure investment or green energy, watch for this boost.

  • Caterpillar (CAT) – infrastructure and construction machinery.

  • NextEra Energy (NEE) – strong in renewables.

  • Quanta Services (PWR) – electric grid, renewables infrastructure.

  • Tesla (TSLA) – if EV incentives ramp up again.


🏥 3. Healthcare & Biotech

Healthcare reform efforts and FDA funding shifts can heavily impact drug and medtech companies.

  • UnitedHealth Group (UNH) – strong during regulatory changes.

  • Eli Lilly (LLY) and Novo Nordisk (NVO) – if focus returns to obesity and diabetes solutions.

  • 10X Genomics (TXG), Twist Bioscience (TWST) – if genomics and biotech innovation get funding support.


🧠 4. Artificial Intelligence & Cybersecurity

Governments are investing in AI infrastructure and cybersecurity regardless of party lines.

  • NVIDIA (NVDA) – chips powering AI.

  • SentinelOne (S) or CrowdStrike (CRWD) – cyber defense.

  • C3.ai (AI) – close to government contracts + enterprise AI.


💻 5. Semiconductors & Reshoring

Both parties push for U.S. manufacturing and chip independence.

  • Intel (INTC) – heavy government backing for fabs.

  • AMD (AMD) and Broadcom (AVGO) – tied to infrastructure and AI buildout.


🏦 6. Financials

Rising interest rates and policy changes may impact banks and fintechs.

  • JPMorgan Chase (JPM) – strong during rising rate environments.

  • Charles Schwab (SCHW) – benefits from investor optimism and capital flows.


🧱 Bonus: "Made in America" Manufacturing Push

If the next administration continues or accelerates reshoring, you might look at:

  • Eaton (ETN) – power management.

  • Generac (GNRC) – tied to grid resilience and climate-driven demand.

  • Enphase Energy (ENPH) – if solar incentives return.


if we go purely by the Presidential Election Cycle Theory, without regard to who's elected or what policies are implemented, the stock picks would shift slightly. Here's how it breaks down:


🔄 Presidential Election Cycle Theory (based on 100 years of market data)

  • Year 1 (Post-election, like 2025):

    • Historically the weakest year for markets, as new policies are introduced and uncertainty is high.

    • However, select sectors still do well, especially those tied to defensive industries and government spending.


📈 Sectors That Have Historically Done Well in Year 1 (like 2025)

  1. Defense & Aerospace

    • Government spending is rarely cut here, and often increases in a new administration.

    • 📌 Picks: Lockheed Martin (LMT), Raytheon (RTX), Northrop Grumman (NOC)

  2. Consumer Staples

    • Investors tend to get more defensive in Year 1, favoring essentials over risk.

    • 📌 Picks: Procter & Gamble (PG), Coca-Cola (KO), PepsiCo (PEP)

  3. Utilities

    • Steady cash flow, dividends, and regulation-protected businesses tend to outperform early in a presidential cycle.

    • 📌 Picks: NextEra Energy (NEE), Duke Energy (DUK)

  4. Healthcare

    • Historically does well early in the cycle due to defensive nature and consistent demand.

    • 📌 Picks: UnitedHealth Group (UNH), AbbVie (ABBV), Pfizer (PFE)


🧠 Less Emphasis on Risk-On Plays (at least early in Year 1)

High-growth sectors like tech, small caps, and speculative AI or biotech often lag in Year 1 of a presidency, unless there's a clear macro tailwind or stimulus policy. So under the pure cycle method, you might de-emphasize:

  • NVIDIA (NVDA)

  • Tesla (TSLA)

  • ARK-style innovation stocks


⏳ When Would Those Growth Stocks Shine Again?

Historically, Year 3 of a presidential cycle (i.e., 2027) is the best year for markets — that’s when risk-on names historically shine again, thanks to:

  • Stimulus before re-election campaigns

  • Low volatility

  • Business-friendly environments


Summary of 2025 Sector Tilt (Based on 100-Year Cycle Alone):

SectorReasonExample Stocks
DefenseNew spending priorities, safe in all climatesLMT, RTX, NOC
Consumer StaplesDefensive, reliable earningsPG, KO, PEP
UtilitiesHigh dividends, stable cash flowNEE, DUK
HealthcareConsistent demand, defensiveUNH, ABBV, PFE

Let’s blend the Presidential Election Cycle theory with the reality of today’s innovation drivers: AI, quantum computing, and healthcare.

🧠 The Strategy:

  • Use the Year 1 (2025) cycle pattern as the foundation (defensives and government-aligned picks).

  • Overlay that with 2025’s megatrends — AI, quantum computing, and healthcare innovation.

  • Choose balanced exposure: stability + growth + innovation, weighted accordingly.


📊 Hypothetical 2025 Portfolio (Balanced & Thematic)

CategoryWeightStock PicksRationale
Defense & Government AI20%Lockheed Martin (LMT)
Palantir Technologies (PLTR)
Defense always gets funding in Year 1. PLTR has deep AI + Gov roots.
Consumer Staples10%Procter & Gamble (PG)
PepsiCo (PEP)
Safe haven during economic/policy transitions.
Utilities (Green Tilt)10%NextEra Energy (NEE)
Brookfield Renewable (BEP)
Stable dividends + clean energy upside.
Healthcare (Core)20%UnitedHealth (UNH)
Eli Lilly (LLY)
Defensive and growth. LLY also has GLP-1 tailwind.
Healthcare (Innovative)10%10X Genomics (TXG)
Twist Bioscience (TWST)
Genomics and synthetic biology play to long-term innovation.
AI Infrastructure (Stable)10%Microsoft (MSFT)
NVIDIA (NVDA)
MSFT for enterprise AI/cloud, NVDA for infrastructure. Both resilient even in choppy years.
AI + Quantum Pure Plays10%C3.ai (AI)
IonQ (IONQ)
Riskier growth, but aligned with megatrend of the decade.
Cash or Short-term Bonds10%BIL (Treasury ETF) or cash equivalentPreserves dry powder for volatility and rotation into growth later in the cycle.

🧩 Optional Tilt Ideas (if you want more flavor)

  • Swap PEP for Costco (COST) if you want retail exposure.

  • Add AbbVie (ABBV) if you want more dividend-friendly healthcare.

  • Add Honeywell (HON) for a hybrid industrial + quantum exposure.


🎯 Portfolio Themes Summary:

  • Cycle-aware: Defensive posture in Year 1.

  • Future-aware: Allocated to the sectors leading the next wave (AI, quantum, genomics).

  • Balanced: Risk is spread across stability (utilities/staples), income (healthcare/defense), and innovation (AI/quantum/genomics).

Now let’s bolt on a “high-risk / high-reward” satellite portfolio that complements your core 2025 cycle-aware + future-tech portfolio.

🎯 Purpose of Satellite Portfolio:

  • Capture explosive upside potential from early-stage or volatile innovators.

  • Lean into speculative AI, quantum, biotech, and frontier tech bets.

  • Accept that some may not perform in Year 1 of the cycle, but could 10x+ in later years.


🚀 Speculative Satellite Portfolio (10-15% of Total Portfolio)

Stock / TickerSectorRationale
C3.ai (AI)AI EnterpriseEarly mover in AI platforms, volatile but visionary — Gov + private AI.
IonQ (IONQ)Quantum TechOne of the few pure-play quantum stocks, backed by AWS/Microsoft.
Recursion Pharma (RXRX)AI + Drug DiscoveryBacked by NVIDIA + using AI to map biology and accelerate pharma pipelines.
Annovis Bio (ANVS)Alzheimer’s BiotechSmall-cap biotech chasing a huge unmet need — big swing on clinical data.
Symbotic (SYM)Robotics/AIAI-powered warehouse robotics, backed by Walmart and SoftBank.
ARK Genomic Revolution ETF (ARKG)Biotech/GenomicsAccess to early-stage genomics, CRISPR, and longevity companies.
BrainChip Holdings (BRCHF)Neuromorphic AISuper speculative — building chips modeled after the human brain.
Zapata AI (ZPTA)Quantum-AIRecent SPAC; combining generative AI with quantum optimization. Very high-risk.

⚠️ Notes:

  • These stocks/companies are more volatile and often not profitable.

  • Some may be thinly traded or prone to sharp corrections on news.

  • Meant to be a smaller piece (10-15%) of your total exposure — think moonshots.


🔧 Allocation Suggestion (If you allocate 15%)

TickerAllocation %
AI2%
IONQ2%
RXRX2%
ANVS2%
SYM2%
ARKG2%
BRCHF1.5%
ZPTA1.5%

ED Note:

This is not investment advice, nor am I an investment advisor. The foregoing is a report created wholly using "Deep Research" Ai using public information from 100 years of Presidential elections. It should be noted, however, that many of Wall Streets elite often refer to the "Election Cycle" metric.

Risk LevelCatalyst to WatchEntry Price Target ($)Stop-Loss Level ($)
HighNew enterprise AI contracts, earnings growth27.020.0
HighGovernment contracts, quantum computing adoption10.07.0
HighPartnerships with pharma, AI platform development7.05.0